Abstract PS5-08-18: Trofuse-011: a phase 3, randomized, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer

Clinical Cancer Research 2026

View at publisher
Authors: Aditya Bardia, X. Peng, K. L. Smith, J. A. Mejia, Hope S. Rugo
DOI: 10.1158/1557-3265.sabcs25-ps5-08-18
Cited by: 0

Abstract

Abstract Background: The standard first-line therapy for most previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS)

Fields of Study & Subjects

Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS5–08
Publication date
17 February 2026
Language
EN